FDA Approved: DICLOFENAC SODIUM — Supplemental Application (Actavis Pharma, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Diclofenac Sodium from Actavis Pharma, Inc. under ANDA074514. The approval covers an updated formulation/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Dysmenorrhea
• Migraine
• Osteoarthritis
• Rheumatoid Arthritis

Drugs mentioned

• DICLOFENAC SODIUM (DICLOFENAC SODIUM)

Snippet

SUPPL AP for DICLOFENAC SODIUM (DICLOFENAC SODIUM)